, Tracking Stock Market Picks
Enter Symbol:
Synovis Life Technologies, Inc. (SYNO) [hlAlert]


Synovis Life Technologies, Inc. (SYNO) rated Hold with price target $14 by Roth Capital

Posted on: Friday,  Dec 4, 2009  9:25 AM ET by Roth Capital

Synovis Life Technologies, Inc. (NASDAQ:
SYNO) rated Hold with price target $14 by Roth Capital.

Synovis Life Technologies, Inc. is a diversified medical device company engaged in developing, manufacturing, marketing and selling implantable biomaterial products, devices for microsurgery and surgical tools. Its products serve an array of medical markets, including general surgery, bariatric, vascular, cardiac, thoracic, neurological and microsurgery. The Company is engaged in the development and manufacturing of implantable biomaterial products for use by surgeons in various procedures where reinforcing, reconstructing and repairing tissue and preventing leaks of air, blood or other body fluids. In January 2008, the Company announced that it had closed on the previously announced sale of substantially all of the assets of its interventional business to Heraeus Vadnais and related entities.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/4/2009 9:25 AM Hold
12.81 14.00
as of 12/31/2009
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/6/2009 8:25 AM Hold
20.64 21.00
12/4/2008 8:25 AM Hold
14.20 16.00
9/30/2008 9:25 AM Hold
19.02 21.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy